ITRM Earnings. Should You Buy?
ITRM Earnings. Should You Buy?: Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the fourth quarter and year ended December 31, 2020. “Iterum has made excellent progress in the last few […]
Comments
Post a Comment